Persistent corneal epithelial defect responding to rebamipide ophthalmic solution in a patient with diabetes

References

• RecchiaFMConnollyBBensonWEOcular manifestations of diabetesCurr Opin Ophthalmol199896646810387338
   PubMedGoogle Scholar
• StangaPEBoydSRHamiltonAMOcular manifestations of diabetes mellitusCurr Opin Ophthalmol199910648348910662255
   PubMedGoogle Scholar
• KajiYPrevention of diabetic keratopathyBr J Ophthalmol200589325425515722297
   PubMed Web of Science ®Google Scholar
• DeMillDLHussainMPop-BusuiRShteinRMOcular surface disease in patients with diabetic peripheral neuropathyBr J Ophthalmol Epub20151023
   Web of Science ®Google Scholar
• UchidaMTabusaFKomatsuMMoritaSKanbeTNakagawaKStudies on 2(1H)-quinolinone derivatives as gastric antiulcer active agents. 2-(4-Chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl] propionic acid and related compoundsChem Pharm Bull (Tokyo)1985339377537864092279
   PubMed Web of Science ®Google Scholar
• YamasakiKKanbeTChijiwaTIshiyamaHMoritaSGastric mucosal protection by OPC-12759, a novel antiulcer compound, in the ratEur J Pharmacol1987142123293480223
   PubMed Web of Science ®Google Scholar
• KleineAKlugeSPeskarBMStimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in ratsDig Dis Sci1993388144114498393757
   PubMed Web of Science ®Google Scholar
• UrashimaHOkamotoTTakejiYShinoharaHFujisawaSRebamipide increases the amount of mucin-like substances on the conjunctiva and cornea in the N-acetylcysteine-treated in vivo modelCornea200423661361915257002
   PubMed Web of Science ®Google Scholar
• RíosJDShatosMUrashimaHTranHDarttDAOPC-12759 increases proliferation of cultured rat conjunctival goblet cellsCornea200625557358116783146
   PubMed Web of Science ®Google Scholar
• KinoshitaSAwamuraSOshidenKRebamipide Ophthalmic Suspension Phase II Study GroupRebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II studyOphthalmology2012119122471247823009892
   PubMed Web of Science ®Google Scholar
• KinoshitaSOshidenKAwamuraSRebamipide Ophthalmic Suspension Phase 3 Study GroupA randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eyeOphthalmology201312061158116523490326
   PubMed Web of Science ®Google Scholar
• TanakaHFukudaKIshidaWHaradaYSumiTFukushimaARebamipide increases barrier function and attenuates TNFα-induced barrier disruption and cytokine expression in human corneal epithelial cellsBr J Ophthalmol201397791291623603753
   PubMed Web of Science ®Google Scholar
• KimuraKMoritaYOritaTHarutaJTakejiYSonodaKHProtection of human corneal epithelial cells from TNF-α-induced disruption of barrier function by rebamipideInvest Ophthalmol Vis Sci201354427522760
   Web of Science ®Google Scholar
• ArakakiREguchiHYamadaAAnti-inflammatory effects of rebamipide eyedrop administration on ocular lesions in a murine model of primary Sjögren’s syndromePLoS One201495e9839024866156
   PubMed Web of Science ®Google Scholar
• ArimotoAKitagawaKMitaNTakahashiYShibuyaESasakiHEffect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusionsCornea201433880681124977983
   PubMed Web of Science ®Google Scholar
• KashimaTAkiyamaHMiuraFKishiSResolution of persistent corneal erosion after administration of topical rebamipideClin Ophthalmol201261403140622969286
   PubMedGoogle Scholar
• TakahashiYIchinoseAKakizakiHTopical rebamipide treatment for superior limbic keratoconjunctivitis in patients with thyroid eye diseaseAm J Ophthalmol2014157480781224412123
   PubMed Web of Science ®Google Scholar
• SasakiHKokubunTAlkali burn treated with 2% rebamipide ophthalmic suspension: a case reportCase Rep Ophthalmol20145338038525762927
   PubMedGoogle Scholar
• ItakuraHKashimaTItakuraMAkiyamaHKishiSTopical rebamipide improves lid wiper epitheliopathyClin Ophthalmol201372137214124204116
   PubMedGoogle Scholar
• ItakuraMItakuraHKashimaTAkiyamaHKishiSTopical rebamipide improves the ocular surface in mild lagophthalmosClin Ophthalmol201371333133823836962
   PubMedGoogle Scholar
• WirostkoBRafiiMSullivanDAMorelliJDingJNovel therapy to treat corneal epithelial defects: a hypothesis with growth hormoneOcul Surf201513320421226045234
   PubMed Web of Science ®Google Scholar
• KanpolatAUçakhanOOTherapeutic use of Focus Night and Day contact lensesCornea200322872673414576523
   PubMed Web of Science ®Google Scholar
• TsubotaKGotoEShimmuraSShimazakiJTreatment of persistent corneal epithelial defect by autologous serum applicationOphthalmology1999106101984198910519596
   PubMed Web of Science ®Google Scholar
• MoritaYMorishigeNYamadaNOhtaMSonodaKHNishidaTRecovery of the corneal stroma associated with rapid reepithelialization induced by the fibronectin-derived peptide PHSRN in 2 cases of corneal perforation due to a persistent epithelial defectCornea201534111504150726312620
   PubMed Web of Science ®Google Scholar
• ToshidaHNguyenDHBeuermanRWMurakamiAEvaluation of novel dry eye model: preganglionic parasympathetic denervation in rabbitInvest Ophthalmol Vis Sci200748104468447517898267
   PubMed Web of Science ®Google Scholar
• YokoiNInatomiTKinoshitaSSurgery of the conjunctivaDev Ophthalmol20084113815818453766
   PubMedGoogle Scholar
• KimJKimCSSohnEJeongIHKimHKimJSInvolvement of advanced glycation end products, oxidative stress and nuclear factor-kappaB in the development of diabetic keratopathyGraefes Arch Clin Exp Ophthalmol2011249452953621104267
   PubMed Web of Science ®Google Scholar
• Ethical Guidelines for Medical and Health Research Involving Human Subjects Provisional Translation (as of March 2015)Ministry of Education, Culture, Sports, Science and Technology; Ministry of Health, Labour and WelfareJapan Available from: http://www.lifescience.mext.go.jp/files/pdf/n1500_01.pdfAccessed April 21, 2016
   Google Scholar